Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.

ABSTRACT:

Background

Sarcopenia refers to the reduction of both volume and number of skeletal muscle fibers. Lean body mass loss is associated with survival, quality of life and tolerance to treatment in cancer patients. The aim of our study is to analyse the association between toxicities and sarcopenia in early breast cancer patients receiving adjuvant treatment.

Materials and methods

Breast cancer patients who have received anthracycline-based adjuvant treatment were retrospectively enrolled. CT scan images performed before, during and after adjuvant chemotherapy were used to evaluate lean body mass at third lumbar vertebra level with the software Slice Omatic V 5.0.

Results

21 stage I-III breast cancer patients were enrolled. According to the skeletal muscle index at third

SUBMITTER: Mazzuca F 

PROVIDER: S-EPMC5986630 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature